past
decad
seen
surg
develop
varieti
molecular
diagnost
design
rapidli
identifi
character
medic
import
microorgan
briefli
review
import
advanc
molecular
microbiolog
discuss
specif
assay
implement
clinic
microbiolog
laboratori
throughout
countri
also
discuss
emerg
method
technolog
soon
wide
use
prompt
accur
detect
agent
infecti
diseas
semin
hematol
elsevi
inc
right
reserv
c
linic
microbiolog
enter
new
era
diagnost
test
molecular
test
transcend
confin
basic
scienc
research
laboratori
becom
import
tool
clinic
laboratori
tradit
cumbersom
polymeras
chain
reaction
pcr
method
given
way
simpler
faster
less
costli
techniqu
use
smaller
clinic
laboratori
lack
extens
train
molecular
method
past
decad
seen
surg
develop
variou
molecular
diagnost
rapidli
identifi
character
infecti
microorgan
test
design
improv
sensit
specif
andor
turnaround
time
convent
method
signific
proport
recent
develop
describ
molecular
test
reason
brief
overview
molecular
microbiolog
provid
follow
discuss
import
advanc
diagnost
test
employ
key
clinic
microbiolog
laboratori
throughout
countri
molecular
microbiolog
divid
three
main
categori
signal
amplif
rapid
cycl
nucleic
acid
amplif
varieti
method
postamplif
analysi
signal
amplif
consist
gener
signal
usual
form
light
color
form
hybrid
occur
probe
complementari
nucleic
acid
sequenc
target
first
molecular
assay
commonli
use
clinic
microbiolog
laboratori
consist
oligonucleotid
acid
probe
use
direct
detect
bacteria
mycobacteria
fungi
situ
hybrid
anoth
type
signal
amplif
reaction
use
human
eye
complex
detect
devic
fluorophorelabel
oligonucleotid
probe
use
hybrid
target
sequenc
fluoresc
signal
observ
use
fluoresc
microscop
procedur
fluoresc
situ
hybrid
fish
although
situ
hybrid
techniqu
use
mani
year
anatom
patholog
research
laboratori
rel
new
clinic
microbiolog
laboratori
number
rapid
cycl
nucleic
acid
amplif
assay
avail
rapid
detect
differenti
need
quantit
microorgan
clinic
specimen
use
pcr
base
chemistri
form
nucleic
acid
amplif
also
avail
rapid
cycl
realtim
format
tradit
pcr
distant
past
took
day
accomplish
often
supplant
faster
userfriendli
rapid
cycl
realtim
pcr
method
assay
perform
close
system
amplif
detect
occur
within
reaction
vessel
open
vessel
manipul
amplicon
unnecessari
greatli
minim
risk
amplicon
contamin
laboratori
significantli
diminish
possibl
subsequ
fals
posit
amplif
result
although
mani
laboratorydesign
verifi
assay
sever
submit
approv
us
food
drug
administr
fda
mani
develop
clinic
trial
monoplex
pcr
refer
detect
singl
target
sequenc
method
commonli
use
qualit
manner
wherein
expect
result
presenc
absenc
microorgan
clinic
specimen
exampl
one
may
use
type
approach
detect
mycobacterium
tuberculosi
legionella
pneumophila
pneumocysti
jiroveci
respiratori
specimen
techniqu
advantag
rapid
diagnosi
seriou
infect
microorgan
slowgrow
fastidi
cultiv
routin
laboratori
multipl
organ
caus
similar
ident
clinic
manifest
intern
amplif
control
desir
multiplex
pcr
reaction
need
two
nucleic
acid
amplif
perform
one
assay
multiplex
assay
address
like
caus
particular
diseas
exampl
communityacquir
pneumonia
diarrhea
would
help
costeffect
way
diagnos
respons
pathogen
mani
instanc
multiplex
assay
recent
develop
virus
caus
mening
two
fdaapprov
assay
avail
rapid
detect
common
respiratori
virus
postamplif
analysi
repres
third
categori
predict
continu
advanc
diagnost
molecular
microbiolog
postamplif
analysi
consist
varieti
method
involv
addit
amplicon
process
analysi
order
obtain
inform
avail
amplif
reaction
alon
postamplif
analysi
allow
accur
identif
character
microorgan
often
speci
level
method
includ
melt
curv
analysi
revers
hybrid
dna
sequenc
microarray
analysi
melt
curv
analysi
consist
differenti
amplifi
dna
product
realtim
pcr
base
probe
dissoci
characterist
brief
amplicon
pcr
reaction
detect
fluoresc
label
oligonucleotid
probe
consum
reaction
fret
eclips
probe
may
yield
addit
inform
base
melt
curv
analysi
oligonucleotid
probe
hybrid
target
sequenc
complementar
particular
dissoci
melt
curv
may
analyz
heat
reaction
mixtur
monitor
fluoresc
nucleotid
polymorph
exist
probe
hybrid
site
melt
curv
shift
amplif
assay
probe
design
afford
microorgan
differenti
postamplif
melt
curv
analysi
type
analysi
use
detect
differenti
tuberculosi
nontubercul
mycobacteria
figur
distinguish
subtyp
herp
simplex
viru
hsv
whiley
et
al
describ
assay
detect
bk
jc
polyomavirus
differenti
one
anoth
base
uniqu
melt
curv
gener
postamplif
melt
curv
analysi
may
also
accomplish
use
nonspecif
dna
binder
like
sybr
green
recent
newer
modif
chemistri
afford
highresolut
melt
curv
analysi
without
need
oligonucleotid
probe
revers
hybrid
simpletoperform
method
detect
varieti
pathogen
follow
either
multiplex
broadrang
amplif
reaction
brief
amplicon
label
appli
nitrocellulos
membran
strip
contain
probe
microorgan
interest
amplicon
hybrid
locat
nitrocellulos
strip
complementari
probe
thereaft
chemic
reaction
demonstr
locat
amplicon
identif
microorgan
interest
therebi
obtain
technolog
use
detect
common
unusu
mycobacteria
human
immunodefici
viru
hiv
hepat
c
viru
hcv
genotyp
frequent
caus
fungal
infect
dna
sequenc
likewis
import
use
diagnost
microbiolog
includ
identif
character
organ
speci
well
strain
level
differenti
eg
multilocu
sequenc
type
mlst
may
also
use
detect
resistanceassoci
mutat
bacteria
fungi
virus
method
postamplif
analysi
consist
determin
nucleic
acid
sequenc
amplicon
usual
either
sanger
pyrosequenc
figur
sequenc
unidentifi
microorgan
determin
queri
genet
databas
find
match
dna
sequenc
becom
alreadi
recogn
method
choic
identifi
mycobacterium
sp
nocardia
aerob
actinomycet
microarray
technolog
use
discoveri
research
mani
year
come
clinic
laboratori
research
tool
capabl
detect
thousand
reaction
simultan
pare
address
complex
diagnost
problem
usual
one
numer
possibl
answer
use
differenti
numer
microbi
pathogen
within
group
well
identifi
larg
varieti
genet
determin
drug
resist
fdaapprov
microarraybas
assay
current
avail
genet
character
patient
cystic
fibrosi
detect
differenti
respiratori
virus
discuss
detail
mani
advanc
tradit
molecular
microbiolog
within
past
year
mani
horizon
follow
brief
review
assay
like
impact
patient
hematolog
disord
risk
opportunist
infect
staphylococcu
aureu
one
common
virul
bacteri
pathogen
respons
signific
proport
nosocomi
infect
two
molecular
test
receiv
fdaapprov
aureu
detect
bd
geneohm
idimrsastaphsr
bd
spark
md
assay
genexpert
mrsa
cepheid
sunnyval
ca
idimrsa
genexpert
approv
methicillinresist
aureu
mrsa
screen
nasal
swab
wherea
staphsr
detect
differenti
mrsa
methicillinsuscept
aureu
mssa
clear
use
posit
blood
cultur
idimrsa
qualit
multiplex
realtim
pcr
assay
mrsaspecif
target
encompass
sequenc
within
sccmecth
mobil
genet
element
contain
meca
geneand
orfx
abil
detect
meca
gene
associ
aureu
coagulaseneg
staphylococci
advantag
test
clinic
specimen
particularli
nasal
swab
contain
microbiota
may
includ
coagulaseneg
staphylococci
intern
amplif
control
includ
order
detect
inhibit
bd
geneohm
staphsr
test
also
multiplex
realtim
pcr
assay
consist
target
mrsa
idimrsa
addit
primer
amplifi
target
sequenc
specif
aureu
modif
afford
differenti
mssa
mrsa
within
hour
blood
cultur
bottl
signal
posit
studi
blood
cultur
posit
gramposit
cocci
stamper
et
al
found
aureu
pcr
compon
assay
sensit
specif
compar
bacteri
cultur
wherea
mrsa
compon
sensit
specif
compar
cultur
suscept
test
overal
neg
predict
valu
npv
posit
predict
valu
ppv
respect
genexpert
mrsa
test
anoth
fdaapprov
molecular
test
mrsa
screen
nasal
swab
genexpert
realtim
pcr
platform
fulli
autom
walkaway
system
requir
minim
expertis
handson
time
total
assay
time
approxim
minut
although
clearli
lead
technolog
respect
easeofus
expens
per
test
comparison
genexpert
mrsa
idimrsa
test
show
compar
sensit
specif
mrsa
detect
nasal
swab
limit
detect
test
nasal
specimen
found
colonyform
unit
cfu
per
swab
compar
direct
cultur
cfu
per
swab
sever
valid
assay
aureu
meca
gene
use
gene
target
mani
year
detect
aureu
may
multiplex
meca
gene
pcr
meca
gene
pcr
may
perform
separ
although
assay
proven
highli
sensit
specif
detect
aureu
meca
gene
limit
includ
inabl
distinguish
mixtur
mssa
methicillinresist
coagulas
neg
staphylococci
mrse
pcr
would
posit
meca
pcr
would
detect
meca
gene
mrse
could
interpret
mrsa
cell
cytotox
assay
present
consid
standard
clostridium
difficil
test
howev
rapid
enzym
immunoassay
eia
test
use
commonli
clinic
laboratori
due
faster
turnaround
time
easeofus
eia
test
vari
wide
sensit
specif
depend
studi
refer
standard
ticehurst
et
al
show
sensit
one
eia
low
compar
test
twostep
diagnost
algorithm
clostridium
difficileassoci
diseas
cdad
consist
screen
glutam
dehydrogenas
gdh
solidphas
eia
c
diff
techlab
blacksburg
va
follow
confirmatori
cell
cultur
cytotox
neutral
assay
ccna
specimen
test
posit
gdh
assay
sensit
screen
gdh
eia
neg
predict
valu
approach
rapidli
screen
neg
specimen
sampl
confirmatori
test
perform
remain
ccna
neg
result
could
report
day
wherea
gdhposit
specimen
incub
anoth
day
ccna
result
could
final
gilligan
also
found
low
sensit
premier
meridian
bioscienc
cincinnati
oh
toxin
b
eia
compar
twostep
diagnost
algorithm
use
screen
gdh
follow
ccna
enhanc
detect
c
difficileposit
specimen
studi
although
gdh
eia
test
easi
perform
give
rapid
result
ccna
portion
assay
laborintens
requir
filtrat
centrifug
step
take
hour
incub
result
final
sever
laboratoryvalid
realtim
pcr
assay
subsequ
develop
demonstr
superior
sensit
compar
eia
also
fast
turnaround
time
easi
use
prospect
multicent
studi
eia
enzymelink
fluoresc
assay
laboratoryverifi
real
timepcr
assay
target
tcdb
gene
ccna
compar
pcr
highest
concord
ccna
refer
standard
recommend
prefer
method
diagnos
cdad
anoth
studi
peterson
colleagu
use
clinic
criteria
part
refer
standard
demonstr
realtim
pcr
significantli
sensit
eia
sensit
sensit
specif
ppv
npv
respect
recent
fda
approv
realtim
pcr
assay
cdad
detect
bd
geneohm
cdiff
assay
bd
geneohm
san
diego
ca
amplifi
highli
conserv
region
tcdb
gene
assay
compar
ccna
wampol
c
difficil
toxin
b
test
toxb
techlab
toxigen
cultur
overal
agreement
high
pcr
assay
ccna
sensit
specif
bd
assay
respect
compar
toxigen
cultur
real
timepcr
prove
sensit
ccna
sensit
specif
detect
c
difficil
fecal
specimen
believ
new
test
algorithm
new
approach
c
difficil
test
repres
signific
advanc
clinic
microbiolog
futur
clinician
like
offer
test
reliabl
help
confirm
exclud
enter
caus
c
difficil
chromogen
media
rapid
culturebas
test
provid
altern
molecular
test
term
cost
need
technic
expertis
equip
use
detect
mrsa
enterococcu
group
b
streptococcu
candida
speci
select
media
contain
proprietari
colorless
chromogen
substrat
cleav
enzym
produc
microorgan
interest
chemic
reaction
result
product
color
therebi
impart
color
entir
coloni
grow
medium
addit
select
may
obtain
incorpor
antibiot
direct
identif
organ
primari
cultur
thu
possibl
within
hour
instanc
product
requir
hour
incub
color
present
fulli
develop
chromid
biomerieux
marci
letoil
franc
select
chromogen
medium
aureu
target
alphaglucosidas
enzym
incorpor
cefoxitin
mgl
growth
mssa
inhibit
cefoxitin
wherea
mrsa
grow
greencolor
coloni
chromagar
mrsa
chromagar
microbiolog
pari
franc
bd
diagnost
erembodegem
belgium
also
contain
cefoxitin
differ
chromogen
reaction
yield
rose
mauv
mrsa
coloni
sensit
assay
vari
somewhat
media
incub
specif
uniformli
high
hour
incub
bacteria
caus
fals
posit
mrsa
id
includ
enterobact
sp
coagulaseneg
staphylococci
con
wherea
chromagar
mrsa
streptococci
con
corynebacterium
spp
gener
extend
incub
chromogen
media
result
increas
sensit
decreas
specif
hour
mrsa
detect
henc
author
recommend
addit
confirmatori
test
form
gram
stain
latex
agglutin
test
improv
specif
especi
incub
time
hour
use
also
import
note
chromogen
media
alon
use
mrsa
screen
mani
mrsacolon
patient
may
miss
compar
realtim
pcr
chromogen
media
rel
new
method
afford
rapid
detect
select
isol
culturebas
format
suffer
mani
limit
cultur
may
sensit
nucleic
acid
amplif
assay
also
mani
benefit
cultur
exampl
organ
avail
subsequ
test
suscept
test
type
product
provid
option
microbiolog
laboratori
yet
readi
offer
molecular
diagnost
test
briefli
describ
tradit
fish
use
fluorophorelabel
oligonucleotid
probe
bind
genet
target
within
cell
peptid
nucleic
acid
probe
pna
use
manner
chemic
uniqu
believ
advantag
dna
oligonucleotid
probe
respect
penetr
across
intact
cell
wall
cell
membran
microorgan
sever
commerci
avail
pna
fish
assay
use
blood
cultur
bottl
signal
posit
particular
organ
morphotyp
present
test
result
obtain
within
approxim
hour
assay
adapt
sever
clinic
laboratori
unit
state
number
public
gener
demonstr
feasibl
improv
clinic
outcom
one
popular
assay
avail
test
aureu
gramposit
cocci
cluster
present
blood
cultur
posit
appear
multipl
cluster
brightli
fluoresc
green
cocci
signifi
presenc
aureu
non
aureu
cocci
cluster
nonfluoresc
sensit
specif
assay
compar
cultur
found
respect
newer
version
contain
probe
aureu
coagulaseneg
staphylococci
wherein
aureu
fluoresc
green
con
red
tradit
molecular
suscept
test
howev
requir
determin
isol
mrsa
also
twocolor
pna
fish
assay
use
rapidli
identifi
enterococcu
faecali
treat
ampicillin
differenti
enterococci
like
resist
drug
well
vancomycin
candida
albican
pna
fish
assay
figur
design
similar
reason
sinc
c
albican
isol
usual
suscept
fluconazol
unless
patient
signific
exposur
drug
two
addit
yeast
pna
assay
approv
use
fda
dual
probe
assay
detect
c
albican
green
candida
glabrata
red
interestingli
recent
releas
assay
definit
identifi
yeast
rather
highlight
speci
like
suscept
fluconazol
green
yellow
either
may
innat
resist
red
assay
c
albican
candida
parapsilosi
highlight
green
candida
tropicali
highlight
yellow
c
glabrata
candida
krusei
highlight
red
assay
produc
rapid
identif
differenti
may
use
guid
antifung
therapi
immunocompromis
patient
increas
risk
diseas
caus
mycobacteria
nocardia
aerob
actinomycet
rapid
determin
presenc
absenc
tuberculosi
respiratori
specimen
critic
clinic
public
health
perspect
tradit
method
timeconsum
laborintens
modif
cultur
method
microscopicobserv
drugsuscept
mod
assay
recent
describ
broth
cultur
perform
multipl
well
view
daili
light
microscopi
magnif
presenc
cord
consid
diagnost
presenc
tuberculosi
assay
sensit
mod
cultur
autom
mycobacteri
cultur
cultur
use
lowensteinjensen
medium
importantli
median
time
cultur
posit
day
day
day
respect
prospect
evalu
brazil
hondura
assay
proven
suitabl
resourcelimit
area
perform
highvolum
test
method
howev
quit
laborintens
timeconsum
laboratori
personnel
two
fdaapprov
nucleic
acid
amplif
test
avail
rapid
detect
tuberculosi
respiratori
specimen
coba
amplicor
tuberculosi
assay
amplicor
roch
diagnost
system
branchburg
nj
amplifi
tuberculosi
direct
test
amtd
genprob
inc
san
diego
ca
test
approv
use
smearposit
sampl
enhanc
version
amtd
test
approv
use
smearposit
case
fda
coba
amplicor
assay
sensit
smearposit
specimen
sensit
much
lower
smearneg
specimen
specif
rang
tuberculosi
exclud
neg
test
posit
assay
use
final
multipl
laboratori
verifi
pcr
assay
describ
use
throughout
world
realtim
pcr
assay
buggraf
et
al
exampl
excel
sensit
specif
compar
coba
amplicor
assay
clinician
awar
fdaapprov
laboratoryverifi
assay
avail
use
rapidli
detect
tuberculosi
particularli
patient
smearposit
respiratori
specimen
dna
probe
technolog
rapid
method
use
mani
year
clinic
mycobacteriologist
rapid
identif
select
mycobacterium
speci
wide
use
assay
commerci
avail
accuprob
genprob
san
diego
ca
assay
suitabl
identif
tuberculosi
complex
mycobacterium
avium
complex
mycobacterium
intracellular
mycobacterium
avium
mycobacterium
intracellulara
combin
mycobacterium
kansasii
mycobacterium
gordona
although
assay
new
laboratori
provid
easyto
use
highli
reliabl
techniqu
rapid
identif
medic
import
mycobacteria
revers
hybrid
line
probe
technolog
also
shown
use
detect
common
less
frequent
encount
mycobacteria
method
biotinyl
pcr
product
afford
opportun
hybrid
correspond
speciesspecif
probe
immobil
nitrocellulos
strip
reaction
form
band
pattern
strip
diagnost
mycobacterium
speci
present
current
two
commerci
avail
assay
innolipa
mycobacteria
innogenet
nv
ghent
belgium
genotyp
mycobacterium
hain
lifesci
nehren
germani
assay
easi
perform
rapidli
accur
detect
mani
mycobacteri
speci
singl
strip
cost
limit
routin
use
otherwis
excel
product
laboratori
dna
sequenc
follow
pcr
current
cornerston
molecularbas
identif
mycobacteria
relat
organ
convent
method
morpholog
biochem
test
requir
week
may
still
yield
ambigu
result
dna
sequenc
provid
rapid
precis
identif
method
led
discoveri
numer
new
mycobacteri
speci
mani
difficult
imposs
differenti
use
phenotyp
method
alon
commonli
use
target
amplif
rrna
heat
shock
protein
rrna
intern
transcrib
spacer
reca
gene
sequenc
obtain
compar
databas
genbank
ribosom
differenti
medic
microsystem
databas
ridom
other
dna
sequenc
also
becom
prefer
method
accur
identif
nocardia
speci
mani
speci
although
genet
distinct
similar
physic
biochem
properti
make
difficult
distinguish
phenotyp
alon
addit
aerob
actinomycet
rhodococcu
gordonia
tsukamurella
also
challeng
identifi
use
tradit
method
may
readili
identifi
dna
sequenc
contrast
tradit
sanger
sequenc
pyrosequenc
novel
method
dna
sequenc
method
also
known
sequenc
synthesi
sinc
sequenc
dna
determin
base
incorpor
nucleotid
strand
dna
synthes
other
use
pyrosequenc
sequenc
select
variabl
region
genom
contain
signatur
identif
mycobacteria
nocardia
select
aerob
actinomycet
respiratori
virus
influenza
b
respiratori
syncyti
viru
rsv
parainfluenza
caus
signific
morbid
mortal
among
young
elderli
within
immunocompromis
popul
recent
standard
diagnost
method
consist
sole
cultur
rapid
immunochromatograph
antigen
immunofluoresc
test
slowli
replac
molecular
diagnost
although
direct
immunofluoresc
assay
dfa
cultur
highli
sensit
specif
labori
timeconsum
multipl
studi
shown
increas
sensit
pcr
dfa
cultur
multiplex
rapid
cycl
pcr
detect
multipl
organ
simultan
specimen
singl
assay
realtim
assay
prodess
waukesha
wi
approv
fda
simultan
detect
influenza
ab
rsv
ab
nasopharyng
specimen
onestep
multiplex
revers
transcript
rt
pcr
take
hour
perform
comparison
immunofluoresc
test
cell
cultur
sensit
assay
influenza
influenza
b
rsv
respect
specif
found
overal
discrep
result
pcrposit
cultureneg
resolv
use
laboratoryverifi
assay
target
differ
gene
target
assay
base
analysi
convent
method
miss
influenza
influenza
b
rsv
infect
anoth
fdaapprov
molecular
test
respiratori
virus
luminex
xtag
rvp
assay
luminex
molecular
diagnost
toronto
ontario
canada
assay
detect
distinct
respiratori
virus
subtyp
three
virus
singl
reaction
abil
detect
influenza
influenza
b
rsv
b
parainfluenza
rhinoviru
adenoviru
coronaviru
sar
hku
human
metapneumoviru
sar
coronaviru
avian
influenza
includ
assay
distribut
canada
contrast
current
cultur
dfa
abil
detect
six
seven
convent
respiratori
virus
prospect
studi
compar
rvp
assay
dfa
cultur
use
nasopharyng
swab
specimen
rvp
test
detect
true
posit
sensit
wherea
latter
detect
sensit
addit
rvp
assay
detect
viru
virus
specimen
viru
detect
dfa
cultur
result
show
greatli
increas
sensit
multiplex
test
compar
convent
method
monitor
cytomegaloviru
cmv
viral
load
blood
essenti
treatment
preemptiv
therapi
cmv
infect
especi
solid
organ
transplant
recipi
sever
quantit
realtim
pcr
assay
develop
well
commerci
avail
pcreia
assay
roch
diagnost
coba
amplicor
cmv
monitor
newer
rapid
cycl
pcr
assay
gener
show
increas
sensit
cmv
antigenemia
assay
earli
detect
cmv
infectionreactiv
benefit
stabil
target
dna
blood
specimen
better
perform
neutropen
patient
greater
accuraci
precis
increas
autom
test
larg
number
specimen
viral
load
monitor
rapidli
becom
alreadi
consid
standard
care
monitor
patient
risk
cmv
diseas
similarli
quantit
assay
commonli
use
epsteinbarr
viru
ebv
bk
polyoma
viru
quantit
ebv
use
monitor
load
viru
blood
patient
risk
ebvassoci
posttranspl
lymphoprolif
disord
quantit
bk
viral
load
assay
monitor
renal
allograft
recipi
known
infect
bk
viru
effort
avoid
bk
nephropathi
assay
although
current
fdaapprov
continu
use
period
assess
patient
risk
ebv
bk
diseas
like
fdaapprov
product
avail
test
within
next
year
enterovirus
common
caus
asept
mening
children
adult
similar
genexpert
platform
rapidli
test
aureu
describ
earlier
manufactur
offer
fulli
autom
realtim
multiplex
rtpcr
assay
enterovirus
fdaapprov
assay
afford
qualit
detect
enteroviru
rna
cerobrospin
fluidspecimen
prospect
studi
seme
et
al
genexpert
dx
system
cepheid
sunnyval
ca
show
excel
agreement
two
pcrbase
assay
detect
enteroviru
rna
csf
sampl
method
rapidli
identifi
yeast
clinic
specimen
particularli
blood
cultur
describ
fungi
filament
fungi
difficult
identifi
may
character
broad
rang
pcr
dna
sequenc
type
test
avail
research
set
larg
refer
laboratori
signific
limit
exist
one
main
reliabl
exist
databas
signific
work
need
done
databas
construct
dna
sequenc
like
continu
employ
potenti
use
frequent
identif
fungi
difficult
identifi
tradit
method
also
numer
opportun
advanc
molecular
diagnost
detect
opportunist
fungal
infect
immunocompromis
host
current
antigenbas
assay
nucleic
acidbas
test
explor
antigenbas
assay
better
standard
commerci
avail
includ
galactomannan
betaglucan
assay
test
allow
clinician
follow
antigen
trend
blood
patient
risk
invas
fungal
infect
similarli
postul
fungal
dna
load
quantifi
result
product
broadrang
fungal
pcr
could
similarli
monitor
follow
patient
risk
opportunist
fungal
infect
potenti
advantag
approach
postamplif
analysi
may
use
discern
ident
infect
fungu
obviou
therapeut
implic
time
wellcontrol
studi
help
determin
method
use
monitor
immunocompromis
host
earli
evid
opportunist
fungal
infect
pneumonia
caus
pneumocysti
jiroveci
pcp
import
diseas
immunocompromis
host
current
standard
diagnosi
direct
identif
use
direct
microscopi
sinc
pcp
cultur
routin
laboratori
number
stain
techniqu
use
strength
limit
realtim
pcr
detect
p
jiroveci
mani
potenti
advantag
morpholog
detect
direct
microscopi
rapid
turnaround
greater
sensit
accuraci
quantit
aspect
rapid
cycl
pcr
also
afford
set
threshold
detect
monitor
patient
undergo
therapi
sever
laboratori
verifi
realtim
pcr
assay
describ
shown
highli
sensit
specif
compar
dfa
laboratori
pcr
shown
superior
toluidin
blue
stain
compar
toluidin
blue
stain
cytopatholog
surgic
patholog
combin
past
decad
wit
advanc
rapid
detect
identif
character
infecti
microorgan
although
improv
culturebas
assay
chromogen
media
aureu
mod
assay
tuberculosi
major
vanguard
work
relat
molecular
diagnost
method
mani
assay
first
perform
sophist
univers
refer
laboratori
made
userfriendli
util
routin
mani
clinic
laboratori
worldwid
complex
molecular
diagnost
use
dna
sequenc
microarray
avail
also
signific
effort
make
assay
easier
use
reproduc
may
implement
diagnost
tool
laboratori
widespread
implement
similar
technolog
undoubtedli
improv
laboratorybas
diagnosi
infecti
diseas
